PMID- 35529728
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231105
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 9
IP  - 56
DP  - 2019 Oct 10
TI  - Enhanced UHPLC-MS/MS determination of a therapeutic heptapeptide mimic for 
      inflammatory-related diseases in rat plasma: application to a pharmacokinetic 
      study.
PG  - 32699-32711
LID - 10.1039/c9ra05114g [doi]
AB  - The seven amino acid peptide, GQTYTSG (named as SP), a peptide mimic derived from 
      hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) has presented 
      remarkable anti-inflammatory activities in previous experiments, indicating that 
      it could be a novel therapeutic peptide candidate for different 
      inflammation-related diseases, such as HCV infection and asthma. A heptapeptide 
      mimic discovery study highlighted the need for the development of quantitative 
      bioanalytical assays for measuring the levels of SP. Herein, a reliable and 
      sensitive ultrahigh-performance liquid chromatography (UHPLC) with tandem mass 
      spectrometry (MS/MS) assay was established and validated for the determination of 
      SP in rat plasma. C-11, with two amino acid substitutions compared to SP (Glycine 
      1 and Glycine 7) and a disulfide, acted as an internal standard (IS). SP and C-11 
      were isolated from acidified plasma using protein precipitation and the extracts 
      were analyzed by reversed-phase UHPLC-MS/MS detection. We used an SHIM-PACK GISS 
      C18 (2.1 x 100 mm, 1.9 mum) column with water containing 0.2% acetic acid as the 
      aqueous mobile phase and methanol as the organic mobile phase with a 0.3 mL 
      min(-1) flow rate. We used an AB SCIEX TripleQuad 5500 mass spectrometer 
      equipped with a TurboIon Spray interface and operated it in positive-ion mode. 
      Multiple reaction monitoring (MRM) was used for the quantification of the 
      precursor to the product ion at m/z 713.3 --> 432.2 for SP and m/z 803.2 --> 539.1 
      for IS. The method was fully validated according to the US Food and Drug 
      Administration (FDA) guideline (2018), and provided satisfactory accuracy, 
      precision, and reproducibility for the quantification of SP in rat plasma. 
      Excellent linearity was achieved (r > 0.9977) over a linear dynamic range of 
      0.1-200 ng mL(-1) with a lower limit of quantification (LLOQ) of 0.1 ng mL(-1). 
      The validated assay was applied to gain the pharmacokinetic (PK) parameters and 
      the concentration-time profile for SP after subcutaneous administration in rats.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Li, Liang
AU  - Li L
AD  - Center for Pharmacological Evaluation and Research, Shanghai Institute of 
      Pharmaceutical Industry, China State Institute of Pharmaceutical Industry 
      Shanghai 200437 PR China liulisipi@foxmail.com +8621-65043855.
AD  - State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR 
      China.
AD  - Shanghai Professional and Technical Service Center for Biological Material 
      Drug-Ability Evaluation Shanghai 200437 PR China.
FAU - Ma, Shumei
AU  - Ma S
AD  - Department of Pharmacology, School of Pharmacy, Fudan University Shanghai 201203 
      PR China.
FAU - Qin, Yan
AU  - Qin Y
AD  - Center for Pharmacological Evaluation and Research, Shanghai Institute of 
      Pharmaceutical Industry, China State Institute of Pharmaceutical Industry 
      Shanghai 200437 PR China liulisipi@foxmail.com +8621-65043855.
AD  - State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR 
      China.
AD  - Shanghai Professional and Technical Service Center for Biological Material 
      Drug-Ability Evaluation Shanghai 200437 PR China.
FAU - Liu, Li
AU  - Liu L
AUID- ORCID: 0000-0002-0986-5540
AD  - Center for Pharmacological Evaluation and Research, Shanghai Institute of 
      Pharmaceutical Industry, China State Institute of Pharmaceutical Industry 
      Shanghai 200437 PR China liulisipi@foxmail.com +8621-65043855.
AD  - State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR 
      China.
AD  - Shanghai Professional and Technical Service Center for Biological Material 
      Drug-Ability Evaluation Shanghai 200437 PR China.
LA  - eng
PT  - Journal Article
DEP - 20191015
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9073091
COIS- There are no conflicts to declare.
EDAT- 2019/10/15 00:00
MHDA- 2019/10/15 00:01
CRDT- 2022/05/09 04:14
PHST- 2019/07/05 00:00 [received]
PHST- 2019/09/21 00:00 [accepted]
PHST- 2022/05/09 04:14 [entrez]
PHST- 2019/10/15 00:00 [pubmed]
PHST- 2019/10/15 00:01 [medline]
AID - c9ra05114g [pii]
AID - 10.1039/c9ra05114g [doi]
PST - epublish
SO  - RSC Adv. 2019 Oct 15;9(56):32699-32711. doi: 10.1039/c9ra05114g. eCollection 2019 
      Oct 10.